- Home
- DDL vs ABVX Comparison
DDL vs ABVX Comparison
Compare DDL & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DDL
- ABVX
- Stock Information
- Founded
- DDL 2014
- ABVX 2013
- Country
- DDL China
- ABVX France
- Employees
- DDL N/A
- ABVX N/A
- Industry
- DDL Catalog/Specialty Distribution
- ABVX
- Sector
- DDL Consumer Discretionary
- ABVX
- Exchange
- DDL Nasdaq
- ABVX Nasdaq
- Market Cap
- DDL 457.4M
- ABVX 451.5M
- IPO Year
- DDL 2021
- ABVX N/A
- Fundamental
- Price
- DDL $2.06
- ABVX $6.02
- Analyst Decision
- DDL
- ABVX Buy
- Analyst Count
- DDL 0
- ABVX 4
- Target Price
- DDL N/A
- ABVX $31.50
- AVG Volume (30 Days)
- DDL 928.6K
- ABVX 193.4K
- Earning Date
- DDL 05-16-2025
- ABVX 03-24-2025
- Dividend Yield
- DDL N/A
- ABVX N/A
- EPS Growth
- DDL N/A
- ABVX N/A
- EPS
- DDL 0.18
- ABVX N/A
- Revenue
- DDL $3,241,404,122.00
- ABVX $11,172,999.00
- Revenue This Year
- DDL $10.17
- ABVX $284.20
- Revenue Next Year
- DDL $16.08
- ABVX N/A
- P/E Ratio
- DDL $11.35
- ABVX N/A
- Revenue Growth
- DDL 17.62
- ABVX 135.94
- 52 Week Low
- DDL $1.62
- ABVX $4.77
- 52 Week High
- DDL $4.79
- ABVX $14.71
- Technical
- Relative Strength Index (RSI)
- DDL 37.66
- ABVX 46.21
- Support Level
- DDL $1.95
- ABVX $5.59
- Resistance Level
- DDL $2.18
- ABVX $6.09
- Average True Range (ATR)
- DDL 0.12
- ABVX 0.33
- MACD
- DDL -0.02
- ABVX -0.02
- Stochastic Oscillator
- DDL 17.95
- ABVX 41.15
About DDL Dingdong (Cayman) Limited (each two representing three)
Dingdong (Cayman) Ltd is the fastest growing on-demand e-commerce company in China. The company directly provides users and households with fresh produce, meat and seafood, and other daily necessities through a convenient shopping experience supported by an extensive self-operated frontline fulfillment grid. It recognizes revenues from product sales of fresh groceries and other daily necessities through Dingdong Fresh APP and mini-programs and membership services.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.